Navigation Links
Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership
Date:11/15/2013

SEATTLE, Nov. 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that members of management will host a conference call today, Friday, November 15, 2013 at 8:30 a.m. ET (5:30 a.m. PT) to discuss today's announcement regarding the worldwide licensing agreement between Baxter International, Inc. and CTI to develop and commercialize pacritinib, CTI's novel investigational JAK2/FLT3 inhibitor currently in Phase 3 development for patients with myelofibrosis.  Access to the event can be obtained as follows:

Friday, November, 15, 2013
5:30 a.m. PT/8:30 a.m. ET/2:30 p.m. CET
1-800-762- 8779(domestic)
+1 480-629-9645 (international)

To access the live audio webcast or the subsequent archived recording, visit www.celltherapeutics.com. Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-406-7325 (domestic) or +1 303-590-3030 (international). The access code for the replay is 4651503. The telephone replay will be available until Friday, November 22, 2013.

About Cell Therapeutics, Inc.
Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at www.CellTherapeutics.com.

Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
eb
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
2. PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
3. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
4. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
5. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
6. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
7. Sorrento Therapeutics Adopts Stockholder Rights Plan
8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
9. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
10. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
11. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael ... clinic, GPM Pediatrics, reacts to a recent study, which shows ... Photo - http://photos.prnewswire.com/prnh/20140723/129709 According ... to severe stress are more likely than others to grow ... before pregnancy." There were two specific types of ...
(Date:7/24/2014)... Deutschland, und MARSEILLE , ... , Weltweite Exklusivlizenz der ... QIAGEN die Entwicklung von Tests auf SF3B1-Mutationen, ... Neuer Test weist Mutationen des ... (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Neurosciences Inc. ("Knopp"),announced that the U.S. Food ... has granted orphan drug designation to KNS-760704 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... to evaluate the safety,tolerability and pharmacokinetics of ...
... to be Treated for This ... Aggressive Cancer at Home, PHILADELPHIA, ... Food and Drug Administration,(FDA) for oral HYCAMTIN(R) (topotecan) capsules for the ... are indicated for patients who had a,complete or partial response to ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 2GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 3GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer 4
(Date:7/27/2014)... July 27, 2014 The inaugural ... demonstrate their passion for protecting our environment and getting ... the Southwest, will go on hiking or camping outings, ... show their support for permanently protecting our land, water ... the Latino community’s perspective on the environment like the ...
(Date:7/27/2014)... Vancouver, BC (PRWEB) July 27, 2014 ... have recently announced their demonstration depicting the hamstring release ... Backs in Action Wellness Center in Vancouver and have ... The hamstring release procedure was carried out by the ... The purpose of the exercise is to release tight ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 This ... Global and Chinese Dutasteride (CAS 164656-23-9) industry. The ... (CAS 164656-23-9) including its classification, application and manufacturing ... top manufacturers of Dutasteride (CAS 164656-23-9) listing their ... etc. , The report further analyzes quantitatively 2009-2014 ...
(Date:7/27/2014)... The European Agricultural Adjuvants Market report ... analysis and forecast of revenue. The agricultural adjuvants market ... million in 2013 to $657.1 million by 2018, at ... Browse through the TOC of the European Agricultural Adjuvants ... analysis provided. It also provides a glimpse of the ...
(Date:7/27/2014)... Bromine market report defines and segments the Bromine market in ... in European region comprises of four major countries. They are ... a dominant share of Bromine market influences the demand for ... the TOC of the Europe Bromine Market report, to get ... TOC of the Europe Bromine Market report. The report provides ...
Breaking Medicine News(10 mins):Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... Executive Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. ... the Philip Morris and R.J. Reynolds tobacco companies ... children by defeating a,ballot initiative to increase Oregon,s ... tobacco companies will profit by selling more cigarettes,while ...
... Solutions Announces Opportunity for Patients to Participate in ... Toward Improved Future Dialysis Options -, WARRENDALE, ... provider of advanced sorbent hemodialysis products and services,today ... has begun using,sorbent technology. The study presents the ...
... ALUS ), a worldwide leader in advanced patient ... financial,results on Tuesday, November 13, 2007, following the market ... the results will follow the,same day at 1:30 p.m. ... open to all interested parties live via the conference ...
... Revenue Impact Projected at $7.5 Million in 2008, ... product,manufacturer, Natural Nutrition Inc., (OTC Bulletin Board: NNTN), ... bar manufacturing capabilities by adding state-of-the-art,equipment to produce ... high,demand today. InterACTIVE Nutrition has been manufacturing ...
... Toronto Stock Exchange Symbol: DND, MISSISSAUGA, ON, Nov. 7 ... and operational results for,the three and nine months ended September ... Entered into a licensing and distribution agreement with ... was granted the exclusive right ...
... Laws Expected to Spread Around the Globe, ATLANTA, ... Society,s ambitious goal to cut cancer incidence by,one-fourth by ... in 2004 than they were in 1992. Despite those ... reduction over the first half of the challenge,period was ...
Cached Medicine News:Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment 2Health News:Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment 3Health News:Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007 2Health News:Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2Health News:Cipher reports third quarter fiscal 2007 results 2Health News:Cipher reports third quarter fiscal 2007 results 3Health News:Cipher reports third quarter fiscal 2007 results 4Health News:Cipher reports third quarter fiscal 2007 results 5Health News:Cipher reports third quarter fiscal 2007 results 6Health News:Cipher reports third quarter fiscal 2007 results 7Health News:Cipher reports third quarter fiscal 2007 results 8Health News:Cipher reports third quarter fiscal 2007 results 9Health News:Cipher reports third quarter fiscal 2007 results 10Health News:Cipher reports third quarter fiscal 2007 results 11Health News:Cipher reports third quarter fiscal 2007 results 12Health News:Cipher reports third quarter fiscal 2007 results 13Health News:Cipher reports third quarter fiscal 2007 results 14Health News:Cipher reports third quarter fiscal 2007 results 15Health News:Cipher reports third quarter fiscal 2007 results 16Health News:Cipher reports third quarter fiscal 2007 results 17Health News:Cipher reports third quarter fiscal 2007 results 18Health News:Cipher reports third quarter fiscal 2007 results 19Health News:Cipher reports third quarter fiscal 2007 results 20Health News:Cancer Incidence in the United States: A Progress Report 2Health News:Cancer Incidence in the United States: A Progress Report 3
... a combination Spectral Optical Coherence Tomography (OCT) ... provides suberb, high-quality images of the vitreo-retina, ... of spectral technology, OTI's sytem can reach ... per second and provide images with a ...
... The Pulse CDC Compact Cardiac Digital Camera is ... an open, patient-friendly gantry, and provides full sized ... camera into your clinic you need a flexible ... layout. Find out how the Pulse reduces ...
... an ideal gamma camera for ... ability to perform bone and ... perfusion diagnosis and SPECT studies. ... and space efficient solution for ...
... analyzer to perform a Chem 7 panel ... Its test panel -- including sodium, potassium, ... creatinine -- represents the most commonly ordered ... hospital. The addition of hematocrit provides valuable ...
Medicine Products: